VEGFA and colorectal carcinoma: Additionally, biological drugs like apatinib (a VEGF inhibitor) and trametinib (a MEK inhibitor) that can inhibit glycolysis, when used in conjunction with ICIs, may enhance therapeutic responses in CRC.